The Translational Systems Core (Core C) will interface with the Project Leaders (Hammond, Roth, and Dillmann), Core A (Farquhar) and Core B (Miyanohara). This shared resource is designed to provide Program scientists, in a single facility, specific techniques that are labor intensive, highly specialized, not generally available to individual laboratories, and expensive. The specific translational systems provided by this Core include detailed cardiovascular physiological studies, the development of cardiovascular disease models, virus vector gene transfer methods, and detailed analysis of excitation-contraction coupling. Physiological assessment will include: i) Transthoracic echocardiography to evaluate cardiac chamber size, wall thickness, and function in vivo;2) Assessment of contractile function of the heart, including measurement of the end-systolic pressure-volume relationship;3) The study of isolated perfused hearts, which will allow more refined and specific measurements of LV contractility in a controlled setting isolated from complex reflex activation and adrenergic activation associated with surgical preparations;4) Telemetry to assess blood pressure and ECG in ambulatory rodents. 4) Detailed cardiac myocyte calcium handling analysis, performed via patch-clamp methods, will be performed at UCLA by a collaborator, Dr Joshua Goldhaber. In addition to providing these studies for all Program Scientists, the Translational Systems Core will provide a highly cost efficient means to conduct such studies in a centralized and well-equipped location, circumventing the need for redundant efforts of individual participating laboratories. By consolidating physiological model development and assessment and viral gene transfer, the cost savings will be considerable.
Translational Core is constantly evolving to bring in state of the art technologies, devise new instrumentation procedures, and develop new disease models in keeping pace with new advances in science and technology.
|Pandey, Amit K; Penny, William F; Bhargava, Valmik et al. (2016) Clinical Evaluation of Heart Failure: Agreement among Tests. PLoS One 11:e0161536|
|Gao, Mei Hua; Giamouridis, Dimosthenis; Lai, N Chin et al. (2016) One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. JCI Insight 1:e88322|
|Schilling, Jan M; Horikawa, Yousuke T; Zemljic-Harpf, Alice E et al. (2016) Electrophysiology and metabolism of caveolin-3-overexpressing mice. Basic Res Cardiol 111:28|
|Cividini, Federico; Scott, Brian T; Dai, Anzhi et al. (2016) O-GlcNAcylation of 8-Oxoguanine DNA Glycosylase (Ogg1) Impairs Oxidative Mitochondrial DNA Lesion Repair in Diabetic Hearts. J Biol Chem 291:26515-26528|
|See Hoe, Louise E; Schilling, Jan M; Busija, Anna R et al. (2016) Chronic Î²1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium. Eur J Pharmacol 789:1-7|
|Tran, Chinh; Stary, Creed M; Schilling, Jan M et al. (2015) Role of caveolin-3 in lymphocyte activation. Life Sci 121:35-9|
|Lai, N Chin; Gao, Mei Hua; Giamouridis, Dimosthenis et al. (2015) Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice. Hum Gene Ther 26:347-56|
|Schilling, Jan M; Roth, David M; Patel, Hemal H (2015) Caveolins in cardioprotection - translatability and mechanisms. Br J Pharmacol 172:2114-25|
|Sun, Junhui; Nguyen, Tiffany; Aponte, Angel M et al. (2015) Ischaemic preconditioning preferentially increases protein S-nitrosylation in subsarcolemmal mitochondria. Cardiovasc Res 106:227-36|
|Markandeya, Yogananda S; Phelan, Laura J; Woon, Marites T et al. (2015) Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase CÎ± in Cardiomyocytes. J Biol Chem 290:22085-100|
Showing the most recent 10 out of 75 publications